Literature DB >> 9209952

Evaluation of UICC TNM classification for pancreatic cancer. A study of 228 patients.

G Balzano1, C Bassi, A Zerbi, M Falconi, G Calori, G Butturini, B E Leone, P Pederzoli, V Di Carlo.   

Abstract

CONCLUSION: A different stage grouping of TNM factors can improve the predictivity of the UICC TNM classification for pancreatic cancer. Nevertheless, the Japanese Pancreas Society (JPS) classification maintains a higher prognostic value.
BACKGROUND: The use of a reliable staging classification facilitates the evaluation of anticancer treatments and the correct management of patients. The aim of the present study was to evaluate the prognostic value of three modified UICC TNM classifications, obtained by different stage grouping of the UICC TNM factors, comparing their predictivity to the standard UICC and the JPS classifications.
METHODS: Clinical material consisted of 228 patients who underwent resection for pancreatic cancer. The reliability of the classifications was analyzed by the following methods: univariate analysis of stage survival curves; multivariate analysis of each classification after adjusting for grading and radicality; and correlation between the patients' distribution in the stages of each classification and in survival classes.
RESULTS: The following modified UICC classification allowed a better differentiation of stage II and III survival (P = 0.08) than standard UICC (P = 0.74): stage I: T1N0M0; stage II: T1N1M0/T2N0M0: stage III: T2N1M0/T3 any NM0; stage IV: M1. The JPS classification better discriminated between the different stages (P < 0.001). All classifications had an independent prognostic value by multivariate analysis. The correlation between stages and survival classes was higher for the JPS classification than either UICC TNM classification or the modified UICC classifications.

Entities:  

Mesh:

Year:  1997        PMID: 9209952     DOI: 10.1007/bf02822382

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  8 in total

1.  UICC and Japanese stage classifications for carcinoma of the pancreas.

Authors:  T Tsunoda; K Ura; T Eto; T Matsumoto; R Tsuchiya
Journal:  Int J Pancreatol       Date:  1991-04

2.  Multivariate survival analysis using Cox's regression model.

Authors:  E Christensen
Journal:  Hepatology       Date:  1987 Nov-Dec       Impact factor: 17.425

3.  Importance of pathologic staging in the surgical management of adenocarcinoma of the exocrine pancreas.

Authors:  A S Hermreck; C Y Thomas; S R Friesen
Journal:  Am J Surg       Date:  1974-06       Impact factor: 2.565

4.  [New aspects of pancreatic carcinoma (author's transl)].

Authors:  G Klöppel; J Sosnowski; H P Eichfuss; K Rückert; R Klapdor
Journal:  Dtsch Med Wochenschr       Date:  1979-12-21       Impact factor: 0.628

5.  Staging of pancreatic cancer: suggestions for a simplified, reliable modification of the TNM classification system.

Authors:  C Bassi; G Butturini; M Falconi; C Iacono; G Serio; P Pederzoli
Journal:  Int J Pancreatol       Date:  1995-04

6.  Reliability of pancreatic cancer staging classifications.

Authors:  A Zerbi; G Balzano; R Bottura; V Di Carlo
Journal:  Int J Pancreatol       Date:  1994-02

7.  Staging of cancer of the pancreas. Cancer of the Pancreas Task Force.

Authors: 
Journal:  Cancer       Date:  1981-03-15       Impact factor: 6.860

8.  Histological and fine structural features of pancreatic ductal adenocarcinomas in relation to growth and prognosis: studies in xenografted tumours and clinico-histopathological correlation in a series of 75 cases.

Authors:  G Klöppel; G Lingenthal; M von Bülow; H F Kern
Journal:  Histopathology       Date:  1985-08       Impact factor: 5.087

  8 in total
  1 in total

1.  p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb.

Authors:  Berthold Gerdes; Annette Ramaswamy; Andreas Ziegler; Sven A Lang; Michael Kersting; Renate Baumann; Anja Wild; Roland Moll; Matthias Rothmund; Detlef K Bartsch
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.